Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on MRNS. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Royal Bank of Canada lowered their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Down 2.1 %

Marinus Pharmaceuticals stock opened at $0.24 on Friday. The firm has a fifty day moving average of $0.57 and a 200-day moving average of $1.13. Marinus Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $11.26. The firm has a market capitalization of $13.16 million, a P/E ratio of -0.10 and a beta of 1.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Franklin Resources Inc. lifted its holdings in Marinus Pharmaceuticals by 34.9% in the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the last quarter. World Investment Advisors LLC bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the last quarter. Suvretta Capital Management LLC boosted its position in Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares during the period. Finally, GSA Capital Partners LLP grew its stake in Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after buying an additional 817,050 shares during the last quarter. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.